Modulators of prostate-specific G-protein receptor (PSGR/OR51E2) and methods of using same

• US 10,588,884 B2
• Filed: 11/01/2017
• Issued: 03/17/2020
• Est. Priority Date: 11/01/2016
• Status: Active Grant

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Abaffy, Tatjana, Matsunami, Hiro
• Primary Examiner(s): Chu, Yong L
• Application Number:
  US15/801,258
• Publication Number:
  US 20180116992A1
• Time in Patent Office: 867 Days
• Field of Search: None
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/7016 Disaccharides, e.g. lactose, lactulose lactobionic acid A61K31/7032
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Abstract

The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.

Claims

1. A method of treating prostate cancer or preventing the progression of prostate cancer in a subject in need thereof, comprising:

administering to the subject a composition consisting of a therapeutically effective amount of one or more OR51E2 ligands and optionally one or more pharmaceutically acceptable carriers, excipients, adjuvants, and diluents, wherein the one or more OR51E2 ligands is 13-cis retinoic acid, or isomers thereof, wherein the one or more ligands binds to OR51E2 on a prostate cancer cell and impedes the progression of the prostate cancer cell, and wherein the prostate cancer cell is a castrate resistant prostate cancer cell.

2. The method of claim 1, wherein the OR51E2 ligandS is 13-cis retinoic acid.

3. The method of claim 1, wherein the subject suffers from chronic infection or inflammation.

4. The method of claim 1, wherein the subject suffers from a P. acnes infection.

5. A method of impeding the progression of a prostate cancer cell, comprising contacting the prostate cancer cell with one or more OR51E2 ligands, wherein the one or more OR51E2 ligands is selected from the group consisting of 13-cis retinoic acid and isomers thereof, and wherein the prostate cancer cell is a castrate resistant prostate cancer cell.

6. The method of claim 5, wherein the OR51E2 ligands is 13-cis retinoic acid.